Astellas and Medivation Receive Priority Review from FDA for XTANDI® (Enzalutamide) Capsules In Chemotherapy-Naive Advanced Prostate Cancer

[PR Newswire] – TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ — Astellas Pharma Inc. (TSE:4503) and Medivation Inc. (MDVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application more

View todays social media effects on MDVN

View the latest stocks trending across Twitter. Click to view dashboard

See who Medivation is hiring next, click here to view